Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
AbstractEndometrial Cancer (EC) is an important cause of death in women worldwide. Despite early diagnosis and optimal treatment of localized disease, relapsed patients have few therapeutic options because after first line therapy, currently no standard of care exists. On the basis of endocrine positivity of most endometrioid ECs, Endocrine Therapy (ET) is a reasonable and widely accepted option. Better knowledge of molecular mechanisms involved in cancer highlighted the deregulated activity of Cyclin-Dependent Kinases (CDKs) in the cell cycle as a hallmark of carcinogenesis supporting the development of a new class of drugs: CDK inhibitors (CDKis). The aim of this review is to give an overview on CDKis preclinical, early clinical activity and future development in EC. Use of CDKis has a strong preclinical rationale but we have poor clinical data. Similar to breast cancer, most ongoing trials are investigating synergistic associations between CDKis and ET. These trials will probably help in defining the best clinical setting of CDKis in ECs, which are the best partner drugs, and how to manage CDKis toxicities with a focus on potential biomarkers of response. View Full-Text
Share & Cite This Article
Giannone, G.; Tuninetti, V.; Ghisoni, E.; Genta, S.; Scotto, G.; Mittica, G.; Valabrega, G. Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer. Int. J. Mol. Sci. 2019, 20, 2353.
Giannone G, Tuninetti V, Ghisoni E, Genta S, Scotto G, Mittica G, Valabrega G. Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer. International Journal of Molecular Sciences. 2019; 20(9):2353.Chicago/Turabian Style
Giannone, Gaia; Tuninetti, Valentina; Ghisoni, Eleonora; Genta, Sofia; Scotto, Giulia; Mittica, Gloria; Valabrega, Giorgio. 2019. "Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer." Int. J. Mol. Sci. 20, no. 9: 2353.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.